EPA:ALNEV - Euronext Paris - Matif - FR001400TG47 - Common Stock - Currency: EUR
EPA:ALNEV (3/7/2025, 7:00:00 PM)
0.0707
-0.01 (-13.68%)
The current stock price of ALNEV.PA is 0.0707 EUR. In the past month the price decreased by -64.65%. In the past year, price decreased by -100%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
NEOVACS
3-5, Impasse Reille
Paris ILE-DE-FRANCE FR
Employees: 22
Company Website: https://www.neovacs.com/fr/
Phone: 33153109300
The current stock price of ALNEV.PA is 0.0707 EUR. The price decreased by -13.68% in the last trading session.
The exchange symbol of NEOVACS is ALNEV and it is listed on the Euronext Paris - Matif exchange.
ALNEV.PA stock is listed on the Euronext Paris - Matif exchange.
NEOVACS (ALNEV.PA) has a market capitalization of 19.09K EUR. This makes ALNEV.PA a Nano Cap stock.
NEOVACS (ALNEV.PA) currently has 22 employees.
NEOVACS (ALNEV.PA) has a resistance level at 0.08. Check the full technical report for a detailed analysis of ALNEV.PA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALNEV.PA does not pay a dividend.
NEOVACS (ALNEV.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.66).
ChartMill assigns a fundamental rating of 1 / 10 to ALNEV.PA. ALNEV.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ALNEV.PA reported a non-GAAP Earnings per Share(EPS) of -9.66. The EPS increased by 100% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -80.72% | ||
ROE | -190.29% | ||
Debt/Equity | 0.03 |
ChartMill assigns a Buy % Consensus number of 87% to ALNEV.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.